{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+ALL&page=2", "query": { "condition": "Philadelphia-Positive ALL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+ALL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T10:54:31.588Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06051409", "title": "A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ph+ ALL", "Leukemia, Lymphoblastic, Acute, Philadelphia-Positive" ], "interventions": [ { "name": "Olverembatinib", "type": "DRUG" }, { "name": "Investigator's choice of TKI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2023-08-31", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051409" }, { "nct_id": "NCT00008307", "title": "Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "syngeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Year to 80 Years" }, "enrollment_count": 52, "start_date": "1998-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008307" }, { "nct_id": "NCT07644351", "title": "A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2024-12-16", "completion_date": "2025-09-17", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07644351" }, { "nct_id": "NCT00038610", "title": "Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 54, "start_date": "2001-03", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-09-18", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038610" }, { "nct_id": "NCT00452023", "title": "Pegasys® in Patients With Myeloproliferative Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders" ], "interventions": [ { "name": "IFN-alpha2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2005-04-07", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452023" }, { "nct_id": "NCT00363649", "title": "Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "GM-K562 cell vaccine", "type": "BIOLOGICAL" }, { "name": "Interferon alfa", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2006-09", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2018-11-13", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363649" }, { "nct_id": "NCT00980018", "title": "An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Nilotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2009-12", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2021-07-01", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 19, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Los Angeles, California + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980018" }, { "nct_id": "NCT00003239", "title": "Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Recombinant Interferon Alfa", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Omacetaxine Mepesuccinate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 90, "start_date": "1998-03", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003239" }, { "nct_id": "NCT01100658", "title": "Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "ALL, Childhood", "Leukemia, Lymphoblastic", "Leukemia, Lymphoblastic, Acute", "Leukemia, Lymphoblastic, Acute, L1", "Leukemia, Lymphoblastic, Acute, L2", "Leukemia, Lymphoblastic, Acute, Philadelphia-Positive", "Leukemia, Lymphocytic, Acute", "Leukemia, Lymphocytic, Acute, L1", "Leukemia, Lymphocytic, Acute, L2", "Lymphoblastic Leukemia", "Lymphoblastic Leukemia, Acute", "Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Leukemia, Acute, L1", "Lymphoblastic Leukemia, Acute, L2", "Lymphoblastic Lymphoma", "Lymphocytic Leukemia, Acute", "Lymphocytic Leukemia, L1", "Lymphocytic Leukemia, L2", "Brain Tumors", "Cancer of the Brain", "Cancer of Brain", "Malignant Primary Brain Tumors", "Brain Neoplasms, Malignant" ], "interventions": [ { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 1, "start_date": "2010-05", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2015-03-27", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01100658" }, { "nct_id": "NCT06773936", "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "CD19+ Acute Leukemia" ], "interventions": [ { "name": "Induction Phase", "type": "DRUG" }, { "name": "Re-Induction Phase", "type": "DRUG" }, { "name": "Post-Remission", "type": "DRUG" }, { "name": "Maintenance", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 55, "start_date": "2026-05-15", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-26T10:54:31.588Z", "location_count": 8, "location_summary": "Orange, California • Lake Success, New York • Rochester, New York + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Lake Success", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06773936" } ] }